About
Technology
Issues
FAQ
Links
Official Page
Safety and Immunogenicity of a Recombinant Protein RBD Fusion Heterodimer Vaccine against SARS-CoV-2: preliminary results of a phase 1-2a dose-escalating, randomized, double-blind clinical trial
site/software ©
exaly
; All materials licenced under
CC by-SA
.